IRVINE, Calif., April 11, 2011 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it has entered into a strategic partnership with Clarient, Inc., a GE Healthcare Company, that allows Clarient the right to commercialize the CombiMatrix DNAarray™ product portfolio. The DNAarray tests are based on aCGH technology, which provides physicians a comprehensive genomic profile of solid cancer tumors and blood-based cancers, helping to better guide patient treatment decisions.
